Affimed NV (NASDAQ:AFMD) shares were down 11.1% during trading on Friday . The stock traded as low as $2.53 and last traded at $2.57, approximately 2,433,867 shares changed hands during trading. An increase of 235% from the average daily volume of 726,686 shares. The stock had previously closed at $2.89.
Several research analysts have recently commented on AFMD shares. Zacks Investment Research cut shares of Affimed from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. ValuEngine raised shares of Affimed from a “sell” rating to a “hold” rating in a report on Wednesday, August 28th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $6.36.
The firm has a market capitalization of $190.91 million, a P/E ratio of -6.76 and a beta of 2.91. The business’s 50 day moving average is $2.96 and its 200-day moving average is $3.03. The company has a quick ratio of 3.47, a current ratio of 3.48 and a debt-to-equity ratio of 0.02.
Hedge funds and other institutional investors have recently made changes to their positions in the company. State of New Jersey Common Pension Fund D acquired a new position in shares of Affimed during the second quarter valued at about $29,000. Parametric Portfolio Associates LLC acquired a new position in shares of Affimed during the second quarter valued at about $41,000. Meeder Asset Management Inc. bought a new stake in shares of Affimed during the third quarter worth about $47,000. Mackenzie Financial Corp bought a new stake in shares of Affimed during the second quarter worth about $47,000. Finally, JPMorgan Chase & Co. bought a new stake in shares of Affimed during the second quarter worth about $47,000. Hedge funds and other institutional investors own 51.01% of the company’s stock.
Affimed Company Profile (NASDAQ:AFMD)
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Featured Article: Total Return
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.